Edler, Peta and Rajasekhar, Megha and Price, David J. and Adam, Ishag I. and Awab, Ghulam Rahim and Barber, Bridget E. and Brasil, Larissa Wanderley and Chamma-Siqueira, Nathália N. and Chu, Cindy S. and Cui, Liwang and Daher, André Bastos and Gomes, Margarete Do Socorro Mendonça and González-Cerón, Lilia and Grigg, Matthew J. and Karunajeewa, Harin A. and Lacerda, Marcus V. G. and Ladeia-Andrade, Simone and Leslie, Toby J. and Ley, Benedikt B. and Lidia, Kartini and Llanos-Cuentas, E. Alejandro and Longley, Rhea J. and Manning, Laurens A. and Mekonnen, Daniel Abebe and Monteiro, Wuelton Marcelo and Moore, Brioni R. and Nosten, François Henri and Pasaribu, Ayodhia Pitaloka and Batista Pereira, Dhelio Batista and Poespoprodjo, Jeanne Rini and Pukrittayakamee, Sasithon and Rijal, Komal Raj and Saravu, Kavitha and Siqueira, Andre M. and Sutanto, Inge and Taylor, Walter Robert John and Thanh, Pham Vinh and Thriemer, Kamala L. and Vieira, José Luiz Fernandes and White, Nicholas J. and Yeshiwondim, Asnakew K. and Zuluaga-Idárraga, Lina Marcela and Guérin, Philippe Jean Jean and Simpson, Julie A. and Price, Ric N. and Commons, Robert J. and Woyessa, Adugna and Woon, Sze Ann and Woodrow, Charles Jonathan and William, Timothy and Von-Seidlein, Lorenz and Viana, Giselle Maria Rachid and Tadesse, Fitsum Girma and Suarez-Kurtz, Guilherme and Sattabongkot, Jetsumon S.P. and Rowland, Mark W. and de Pina-Costa, Anielle and Nelwan, Erni Juwita and Negreiros, Suiane C. and Naadim, Mohammad Nader and Mueller, Ivo and Mekuria, Asrat Hailu and Kumar, Rishikesh and Koh, Gavin C.K.W. and Khan, Wasif Ali and Hwang, Jimee and Hassanzai, Mohammad Anwar and Green, Justin A. and Ghimire, Prakash Chandra and Ghanchi, Najia Karim and Gadisa, Endalamaw and Ferreira, Marcelo Urbano and Erhart, Annette and Dondorp, A. M. and Degaga, Tamiru Shibiru and Day, Nicholas P.J. and Chau, Nguyen Hoang and Boyd, Sarah C. and Baird, John Kevin and Assefa, Ashenafi and Anstey, Nicholas M. and Alam, Mohammad Shafiul and Adhikari, Bipin and Abreha, Tesfay (2025) Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis. Malaria Journal, 24 (1): 400. ISSN 14752875
![[thumbnail of Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis _ Enhanced Reader.pdf]](https://ir.lib.ugm.ac.id/style/images/fileicons/text.png)
Text
Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis _ Enhanced Reader.pdf - Published Version
Restricted to Registered users only
Available under License Creative Commons Attribution.
Download (3MB) | Request a copy
Abstract
Background: The antirelapse efficacy of primaquine is related to the total dose administered, whereas the risks of haemolysis and gastrointestinal intolerance are associated with the daily dose administered. National Malaria Control Programmes require local information on efficacy, tolerability and safety to optimize antimalarial treatment policies for Plasmodium vivax malaria control and elimination efforts. Methods: A living systematic review identified efficacy studies of uncomplicated P. vivax malaria including patients treated with daily primaquine regimens, published since January 1, 2000. Available data were pooled and an R Shiny app was developed to integrate statistical analyses performed using R and Stata that assessed the impact of primaquine mg/kg dose on efficacy, hematological safety and gastrointestinal tolerability. Results: As of January 16, 2025, a total of 9,270 individual patient data records from 41 studies have been collated into the standardized repository. Open-access automated reports were generated for user-selected countries or regions to investigate location specific effects of primaquine dose on efficacy, safety and tolerability. The reports include visual and tabular displays of the outcomes. Conclusions: These automated reports leverage a large database to provide accessible data for national and regional policy makers and researchers to assess the clinical consequences of different primaquine regimens in different endemic settings. The reports will inform local and regional policy decisions and research priorities in vivax-endemic areas. © The Author(s) 2025.
| Item Type: | Article |
|---|---|
| Additional Information: | Cited by: 0; All Open Access; Gold Open Access; Green Accepted Open Access; Green Final Open Access; Green Open Access |
| Uncontrolled Keywords: | hemoglobin; primaquine; antimalarial agent; antimalarial drug resistance; Article; drug efficacy; drug megadose; drug safety; drug tolerability; feedback system; follow up; hemolysis; human; low drug dose; meta analysis; Plasmodium vivax malaria; recurrent disease; systematic review; drug effect; drug therapy; Plasmodium vivax; treatment outcome; Antimalarials; Humans; Malaria, Vivax; Primaquine; Treatment Outcome |
| Subjects: | R Medicine > RJ Pediatrics |
| Divisions: | Faculty of Medicine, Public Health and Nursing > Non Surgical Divisions |
| Depositing User: | Ani PURWANDARI |
| Date Deposited: | 10 Mar 2026 06:58 |
| Last Modified: | 10 Mar 2026 06:58 |
| URI: | https://ir.lib.ugm.ac.id/id/eprint/25966 |
Actions (login required)
- View Item